Zydus launches SoviHep – the breakthrough hepatitis C therapy in alliance with Gilead
The breakthrough oral therapy, SoviHep, a generic version of sofosbuvir, which will provide treatment to more than 10 million patients who suffer from hepatitis C in India, has been launched by Indian drugmaker the Zydus Cadila. Shares of parent company Cadila Healthcare (BSE: 532321) surged 8.13% to 1,715 rupees on the Bombay Stock Exchange following the news.
US biotech major Gilead Sciences (Nasdaq: GILD) had signed a non-exclusive licensing agreement with Zydus and other generic drugmakers which will allow the manufacture of sofosbuvir (trade name Sovaldi) and the fixed-dose combination of ledipasvir/sofosbuvir (trade name Harvoni) for distribution in 91 countries including India. The therapy will be marketed by the specialty division of the group, Zydus Heptiza.
“Bridges a longstanding unmet health care need”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze